The global shift toward self-administered therapies for chronic diseases has placed unprecedented demands on pharmaceutical packaging. As biologics, insulin, GLP-1 therapies, and follicle-stimulating hormone (FSH) treatments become more prevalent, manufacturers require packaging partners capable of delivering precision, stability, and regulatory compliance at scale. Among the companies...